{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytochrome+P450+%28CYP%29+Substrates", "query": { "intervention": "Cytochrome P450 (CYP) Substrates" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytochrome+P450+%28CYP%29+Substrates&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T23:32:24.186Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05657613", "title": "Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interactions" ], "interventions": [ { "name": "CYP450 Cocktail and Transporter Substrates with Pacritinib", "type": "DRUG" }, { "name": "Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib", "type": "DRUG" }, { "name": "Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 60, "start_date": "2023-01-03", "completion_date": "2023-06-08", "has_results": false, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-09-26T23:32:24.186Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05657613" }, { "nct_id": "NCT03718884", "title": "A Study of Mirikizumab in Participants With Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Drug Cocktail", "type": "DRUG" }, { "name": "Mirikizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2018-10-23", "completion_date": "2019-10-28", "has_results": true, "last_update_posted_date": "2024-01-29", "last_synced_at": "2026-09-26T23:32:24.186Z", "location_count": 3, "location_summary": "Anaheim, California • DeLand, Florida • High Point, North Carolina", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "High Point", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03718884" }, { "nct_id": "NCT03333824", "title": "Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "CYP1A2 (caffeine)", "type": "DRUG" }, { "name": "CYP2C19 (omeprazole)", "type": "DRUG" }, { "name": "CYP3A (midazolam)", "type": "DRUG" }, { "name": "Kytril (granisetron)", "type": "DRUG" }, { "name": "Wee-1 kinase inhibitor AZD1775", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 33, "start_date": "2017-12-01", "completion_date": "2019-01-22", "has_results": false, "last_update_posted_date": "2019-03-25", "last_synced_at": "2026-09-26T23:32:24.186Z", "location_count": 7, "location_summary": "Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more", "locations": [ { "city": "Bingham Farms", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03333824" }, { "nct_id": "NCT01473888", "title": "A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stable Angina" ], "interventions": [ { "name": "T89(Dantonic)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tasly Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 24, "start_date": "2011-01", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-11-08", "last_synced_at": "2026-09-26T23:32:24.186Z", "location_count": 1, "location_summary": "Tacoma, Washington", "locations": [ { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01473888" }, { "nct_id": "NCT02760615", "title": "Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Colitis, Ulcerative", "Crohn Disease" ], "interventions": [ { "name": "Caffeine", "type": "DRUG" }, { "name": "Losartan", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Dextromethorphan", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Vedolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2016-11-01", "completion_date": "2020-08-01", "has_results": false, "last_update_posted_date": "2020-10-27", "last_synced_at": "2026-09-26T23:32:24.186Z", "location_count": 2, "location_summary": "Cypress, California • Miami, Florida", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02760615" }, { "nct_id": "NCT04254783", "title": "A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ulcerative Colitis (UC)", "Crohn's Disease" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" }, { "name": "Cytochrome P450 (CYP) Substrates", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2020-05-27", "completion_date": "2022-10-14", "has_results": false, "last_update_posted_date": "2024-07-01", "last_synced_at": "2026-09-26T23:32:24.186Z", "location_count": 4, "location_summary": "Coronado, California • DeLand, Florida • Margate, Florida + 1 more", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Margate", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04254783" }, { "nct_id": "NCT05175352", "title": "A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Eosinophilic Esophagitis" ], "interventions": [ { "name": "Cendakimab", "type": "DRUG" }, { "name": "CYP substrates", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 16, "start_date": "2022-06-07", "completion_date": "2024-10-11", "has_results": false, "last_update_posted_date": "2024-12-20", "last_synced_at": "2026-09-26T23:32:24.186Z", "location_count": 12, "location_summary": "Tucson, Arizona • Los Angeles, California • San Diego, California + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Bristol", "state": "Connecticut" }, { "city": "Inverness", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05175352" }, { "nct_id": "NCT02688088", "title": "A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Metastasis" ], "interventions": [ { "name": "Drug Cocktail", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2016-03-08", "completion_date": "2021-01-06", "has_results": true, "last_update_posted_date": "2022-10-18", "last_synced_at": "2026-09-26T23:32:24.186Z", "location_count": 5, "location_summary": "Denver, Colorado • Indianapolis, Indiana • Fairway, Kansas + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02688088" }, { "nct_id": "NCT05891119", "title": "Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Caffeine", "type": "DIETARY_SUPPLEMENT" }, { "name": "Metoprolol", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Vitamin K", "type": "DIETARY_SUPPLEMENT" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Rocatinlimab", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 21, "start_date": "2023-06-03", "completion_date": "2025-02-12", "has_results": false, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-09-26T23:32:24.186Z", "location_count": 7, "location_summary": "North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more", "locations": [ { "city": "North Hollywood", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Dilworth", "state": "Minnesota" }, { "city": "Camp Hill", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05891119" }, { "nct_id": "NCT07486713", "title": "Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "AML (Acute Myeloid Leukemia)", "Glioma", "Cholangiocarcinoma", "Solid Tumor Malignancies" ], "interventions": [ { "name": "Olutasidenib", "type": "DRUG" }, { "name": "CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rigel Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2026-02-23", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-26T23:32:24.186Z", "location_count": 2, "location_summary": "Orange, California • New York, New York", "locations": [ { "city": "Orange", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07486713" } ] }